BeOne Medicines reported robust third quarter 2026 results, driven by the continued commercial expansion of its flagship BTK inhibitor, BRUKINSA. Total revenue increased 34% year-over-year to $1.9 billion, outperforming analyst expectations and prompting management to raise full-year 2026 guidance.
Key Highlights
- Brukinsa Dominance: Global sales of BRUKINSA reached $1.4 billion, a 34% year-over-year increase, fueled by a 36% growth in U.S. sales which totaled $1.0 billion.
- Profitability Expansion: The company delivered GAAP net income of $385 million ($3.28 per ADS), significantly exceeding the $2.34 estimate due to improved operating leverage and revenue growth.
- Guidance Hike: Raised 2026 total revenue guidance to a range of $6.9 billion to $7.0 billion, up from the prior outlook of $6.6 billion to $6.8 billion.
- Operating Efficiency: GAAP operating income rose to $419 million compared to $163 million in the prior-year period, with GAAP gross margins expanding 200 basis points to 88%.
- Pipeline Momentum: The company reported high clinical activity with 29 abstracts accepted for ASH 2026 and received FDA Priority Review for the BRUKINSA Phase 3 MANGROVE filing.